The M230L nonnucleoside reverse transcriptase inhibitor resistance mutation in HIV-1 reverse transcriptase impairs enzymatic function and viral replicative capacity.
PMID: 20852269
2010
The Journal of antimicrobial chemotherapy
Abstract: K103N and M230L conferred high-level resistance to both efavirenz (FC=39 and 15.3, respectively) and nevirapine (FC=43.5 and 33), confirming that M230L confers cross-resistance to both drugs while K103N-containing viruses remain susceptible to etravirine.
Abstract: K103N-containing viruses replicated well in the presence of efavirenz and nevirapine, while virus containing M230L displayed substantial replication in the presence of all NNRTIs tested.
Abstract: METHODS: We compared the effects of K103N, the most prevalent NNRTI resistance mutation, and M230L on enzyme function, virus replication and extent of biochemical
Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors.
Abstract: These included V90I, A98G, L100I, K1O1E/P/Q, K103H/N/S/T, V106A/I/M, V108I, E138G/K/Q, V179D/E/F/G/I, Y181C/I/V, Y188C/H/L, V189I, G190A/C/E/Q/S, H221Y, P225H, F227C/L, M230I/L, P236L, K238N/T and Y318F
In utero HIV infection is associated with an increased risk of nevirapine resistance in ugandan infants who were exposed to perinatal single dose nevirapine.
PMID: 19552593
2009
AIDS research and human retroviruses
Table: M230L
Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors.
PMID: 19734799
2009
Journal of acquired immune deficiency syndromes (1999)
Method: L100I, K101E/P, K103N/S, V106A/M, Y181C/I/V, V179F, Method: Etravirine-resistance mutations were defined as mutations associated in the DUET studies with a decreased virological response to etravirine: V90I, A98G, L100I, K101E/H/P, V106I, E138A, V179D/F/T, Y181C/I/V, G190A/S, and M230L.
Table: M230L
Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa.
Method: The mutations we examined, by drug category were: lamivudine (184I/V); any other nucleoside reverse transcriptase inhibitors (41L, 62V, 65R, 67N, 69D or insertion, 70R, 74V, 75I, 151M, 210W, 215F/Y or 219E/Q); any non-nucleoside reverse transcriptase inhibitors (100I, 103N, 106A/M, 108I, 181C/I, 188C/H/L, 190A/S, P225H, M230L or 236L); and any protease-inhibitors (30N, 33F, 46I/L, 48V, 50L/V, 54V/L/M, 82A/F/S/T, 84V, or 90M).
Short communication: Different mutation patterns in subtype CRF06_cpx after mother-to-child transmission.
PMID: 19032066
2008
AIDS research and human retroviruses
Abstract: GRT during follow-up showed selection of L74V/K103N/M184V/M230L in RT and M46I/H63Q/N88S in PR.
Etravirine: a second-generation NNRTI for treatment-experienced adults with resistant HIV-1 infection.
Conclusion: Etravirine RAMs include V90I, A98G, L100I, K101E/H/P, V106I, E138A, V179D/F/T, Y181C/I/V, G190A/S and M230L.
Conclusion: Mutations most commonly associated with significant etravirine resistance include Y181I, Y181V, K101P and M230L, which were rarely present in clinical isolates.
Introduction: In vitro studies suggest that etravirine selects for L100I, V179F/I,
Table: M230L
HIV-1 subtype B protease and reverse transcriptase amino acid covariation.
Method: NNRTI-selected mutations included A98G, L100I, K101E/P/N/H, K103N/S, V106A/M, V108I, V179D/E, Y181C/I/V, Y188L/C/H, G190A/S/E/Q, P225H, F227L, M230L, P236L, and K238T.
In vitro selection of mutations in human immunodeficiency virus type 1 reverse transcriptase that confer resistance to capravirine, a novel nonnucleoside reverse transcriptase inhibitor.
HIV mutation literature information.
PMID: 
2010
The Journal of antimicrobial chemotherapy
Browser Board
Co-occurred Entities
Filtrator
ViMRT